Analysts Give Amedisys, an Average “Hold” Rating with $109.60 PT

August 13, 2023

🌥️Trending News

Amedisys ($NASDAQ:AMED), Inc. (NASDAQ: AMED) is a leading provider of home health, hospice and personal care services. Thirteen analysts currently monitoring Amedisys, Inc. have assigned it an average rating of “Hold” and an average price target of $109.60. Analysts cite the company’s favorable long-term prospects, though they remain cautious in the near term due to uncertainty regarding reimbursement and competitive pressures. The rating from analysts is based on various factors such as the company’s fundamentals, outlook and current market conditions. Many analysts take into account the company’s past performance as well as its future growth potential when assigning a rating. Amedisys, Inc. has been performing well lately and is expected to continue its strong performance over the coming year. The company has seen strong organic growth and is well positioned to capitalize on favorable industry trends. They have also made some strategic acquisitions to bolster their capabilities. Analysts expect that these factors will result in long-term growth and increased market share for the company.

However, analysts remain cautious in the near term due to continued uncertainty around reimbursement and competitive pressures. The new Medicare reimbursement system could potentially lead to lower reimbursement rates and increased competition could pressure margins further. In conclusion, analysts are generally positive on Amedisys, Inc. in the long-term, but are hesitant to recommend it as a buy in the near term due to uncertainty surrounding reimbursement and competitive pressures.

Price History

The stock opened at $91.8 and closed at $92.0, with a 0.1% increase from the previous closing price of 91.9. Amedisys_an_Average_Hold_Rating_with_109.60_PT”>Live Quote…

About the Company

  • Amedisys_an_Average_Hold_Rating_with_109.60_PT”>Industry Classification
  • Key Executives
  • Ownership (Institutional/ Fund Holdings)
  • News Feed
  • Income Snapshot

    Below shows the total revenue, net income and net margin for Amedisys. More…

    Total Revenues Net Income Net Margin
    2.23k 2.33 3.0%
  • Income Statement Reports (Yearly/ Quarterly/ LTM)
  • Income Supplement
  • Growth Performance
  • Cash Flow Snapshot

    Below shows the cash from operations, investing and financing for Amedisys. More…

    Operations Investing Financing
    113.97 35.25 -86.83
  • Cash Flow Statement (Yearly/ Quarterly/ LTM)
  • Cash Flow Supplement
  • Balance Sheet Snapshot

    Below shows the total assets, liabilities and book value per share for Amedisys. More…

    Total Assets Total Liabilities Book Value Per Share
    1.98k 921.64 30.87
  • Balance Sheet (Yearly/ Quarterly)
  • Balance Sheet Supplement
  • Key Ratios Snapshot

    Some of the financial key ratios for Amedisys are shown below. More…

    3Y Rev Growth 3Y Operating Profit Growth Operating Margin
    4.2% -2.9% 3.3%
    FCF Margin ROE ROA
    4.5% 4.5% 2.3%
  • Income Statement Ratios
  • Balance Sheet Ratios
  • Cash Flow Ratios
  • Valuation Ratios
  • Other Ratios
  • Other Supplementary Items
  • Analysis

    At GoodWhale, our analysis of AMEDISYS‘s fundamentals shows that it has a strong profitability, but is weak in asset, dividend, and growth. AMEDISYS has a high health score of 8/10, indicating that it is capable of paying off its debt and funding its future operations. We have classified AMEDISYS as a ‘sloth’, meaning one that has achieved slower revenue or earnings growth than the overall economy. Investors who are looking for investments that are more stable but may not appreciate as quickly should consider investing in AMEDISYS. Its low risks and steady performance make it an attractive choice for those seeking a stable long-term investment. Additionally, investors who are interested in healthcare related companies may be attracted to AMEDISYS as it’s one of the leading providers of home health and hospice care. More…

  • Risk Rating Analysis
  • Star Chart Analysis
  • Valuation Analysis

  • Peers

    Its competitors include National Healthcare Corp, Aveanna Healthcare Holdings Inc, and Nova Leap Health Corp.

    – National Healthcare Corp ($NYSEAM:NHC)

    National Healthcare Corporation is a diversified healthcare services company that owns and operates long-term care facilities, hospitals, home health agencies, and hospice care businesses. The company has a market capitalization of $942.75 million and a return on equity of 2.65%. National Healthcare Corporation is headquartered in Nashville, Tennessee.

    – Aveanna Healthcare Holdings Inc ($NASDAQ:AVAH)

    Aveanna Healthcare Holdings Inc is a publicly traded company that provides health care services. The company has a market capitalization of 290.03 million as of 2022 and a return on equity of -71.08%. The company’s primary business is providing in-home health care services to patients. The company operates in the United States, Canada, and Puerto Rico.

    – Nova Leap Health Corp ($TSXV:NLH)

    Nova Leap Health Corp is a Canadian publicly traded company with a market cap of 23.25M as of 2022. The company is a provider of home health care services. The company has a Return on Equity of 1.6%. The company’s services include personal care, nursing, and homemaking services.


    Analysts have given Amedisys, Inc. a “Hold” rating with an average price target of $109.60. This suggests that the stock will remain at approximately the same price in the short term. Investing in Amedisys, Inc. is a relatively risky venture due to the uncertain nature of its stock performance in the future.

    It is important to research the company’s financials, as well as its competitive landscape, in order to make an informed decision before investing. Factors such as market demand, economic cycles, and other industry-specific information should be thoroughly considered.

    Recent Posts

    Leave a Comment